GlassScriptPhysician profile
Lawrence M Lehrner
NPI 1083604094
$8,486.50
in general payments reported to CMS, 2019-2025
21 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.50 · 2020: $6,427 · 2022: $465 · 2023: $397 · 2024: $751 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,463.43 | 2020-2024 | Lokelma, Farxiga |
| Biomerieux INC | $442.35 | 2022 | |
| Amgen INC. | $330.26 | 2019-2024 | Tavneos, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.30 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $211.81 | 2023-2025 | |
| Horizon Therapeutics Plc | $178.10 | 2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $123.55 | 2024 | |
| Aurinia Pharma U.S., INC. | $98.13 | 2022-2024 | Lupkynis |
| Merck Sharp & Dohme LLC | $68.93 | 2025 | Prevymis |
| Vifor Pharma, INC. | $51.51 | 2023-2024 | Veltassa, Korsuva |
| Ardelyx, INC. | $43.80 | 2023-2024 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $43.24 | 2019-2024 | Jynarque |
| Apellis Pharmaceuticals, INC. | $35.27 | 2025 | Empaveli |
| Glaxosmithkline, LLC. | $34.29 | 2023 | Benlysta, Jesduvroq |
| Mallinckrodt Hospital Products INC. | $24.80 | 2025 | Terlivaz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $21.98 | 2023 | Rayaldee |
| Novo Nordisk INC | $21.88 | 2024 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $15.42 | 2023 | Gattex |
| Ani Pharmaceuticals, INC. | $14.45 | 2023 | Purified Cortrophin Gel |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Lehrner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.